GlassScriptPhysician profile
Anne E Busseniers
NPI 1679558043
$1,792.91
in general payments reported to CMS, 2019-2025
19 companies · $136 in 2025
The $136 reported for 2025 was more than what a typical Cytopathology provider received nationally (typical 2025 total: $55.75).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $530 · 2021: $413 · 2022: $152 · 2023: $335 · 2024: $20.10 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.55 | 2019-2023 | Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $337.02 | 2020-2024 | |
| Lilly USA, LLC | $217.27 | 2020-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.35 | 2019-2023 | Jardiance |
| Janssen Biotech, INC. | $120.12 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $108.50 | 2020-2025 | |
| Corcept Therapeutics | $81.27 | 2020-2023 | Korlym |
| Novo Nordisk INC | $77.16 | 2021 | |
| Celgene Corporation | $45.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.21 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $41.35 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.66 | 2020 | |
| Radius Health, INC. | $20.23 | 2020 | |
| Glaxosmithkline, LLC. | $19.35 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $17.54 | 2019 | |
| Dexcom, INC. | $16.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.58 | 2020 | |
| Shire North American Group INC | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Busseniers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.